Literature DB >> 31285709

Increase in ST-11 serogroup W Neisseria meningitidis invasive meningococcal disease in Canada, 2016-2018.

R S Tsang1, L Hoang2, G J Tyrrell3, J Minion4, P Van Caeseele5, J V Kus6,7, B Lefebvre8, D Haldane9,10, R Garceau11, G German12, G Zahariadis13,14, B Hanley15.   

Abstract

BACKGROUND: Many countries have experienced increases in invasive meningococcal disease (IMD) due to a serogroup W Neisseria meningitidis (MenW) strain of the multilocus sequence type (ST)-11 clonal complex (CC). MenW ST-11 was first reported in Ontario, Canada, in 2014. By 2016, this strain caused IMD in five provinces and was responsible for 18.8% of the IMD cases in Canada.
OBJECTIVE: To provide an update on invasive MenW disease in Canada including the strain characteristics, specimen source of isolates, age, sex and geographic distribution of cases.
METHODS: N. meningitidis from culture-positive IMD cases are routinely submitted to the National Microbiology Laboratory (NML) for serogroup, serotype, serosubtype and sequence type analysis. The data from January 1, 2016 to December 31, 2018 were analyzed by calculating the proportion of IMD cases caused by MenW compared with other serogroups. In addition, trends based on age, sex and geographic distribution of cases and specimen source of isolates were analyzed based on information on specimen requisition forms.
RESULTS: Over the 3-year period, 292 individual IMD case isolates were analyzed. The percentage of IMD case isolates typed as MenW more than doubled from 19% (n=15) to 44% (n=51) in 2018 when MenW became the most common serogroup, exceeded the number of MenB, MenC or MenY. In total, 93 MenW case isolates were identified, 91% (n=85) belonged to the ST-11 CC. The increase in MenW affected all age groups (but was most common in those older than 60) and both sexes, and occurred across the country but most prevalent in western Canada. The most common specimen source was blood.
CONCLUSION: In 2018, MenW was the most common serogroup for isolates received by the NML from culture-positive IMD cases in Canada. Over 90% of the MenW serogroup isolates belonged to the ST-11 CC. The quadrivalent ACWY meningococcal conjugate vaccine protects against IMD caused by strains in the A, C, W or Y serogroups and therefore may protect against IMD caused by the new MenW ST-11 strain; however, more research is needed. The emergence of variant strains highlight the importance of strain characterization in IMD surveillance and research.

Entities:  

Keywords:  Canada; Neisseria meningitidis; clonal complex; invasive meningococcal disease; sequence type; sequence type-11; serogroup W

Year:  2019        PMID: 31285709      PMCID: PMC6587698          DOI: 10.14745/ccdr.v45i06a04

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  24 in total

1.  An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2001-10-15

2.  DNA Sequence analysis of the PorB protein of nonserotypeable serogroup C ET-15 meningococci suggests a potential mutational hot spot on their serotype antigens.

Authors:  Dennis K S Law; Averil M Henderson; Raymond S W Tsang
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

3.  Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001.

Authors:  S G Squires; S L Deeks; R S Tsang
Journal:  Can Commun Dis Rep       Date:  2004-02-01

4.  Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2006-04-15

5.  Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2007-06-01

Review 6.  Global epidemiology of meningococcal disease.

Authors:  Lee H Harrison; Caroline L Trotter; Mary E Ramsay
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

Review 7.  Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.

Authors:  C E Frasch; W D Zollinger; J T Poolman
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

8.  Genetic and antigenic characterization of invasive endemic serogroup B Neisseria meningitidis from Ontario, Canada, in 2001-2010.

Authors:  Frances B Jamieson; Prasad Rawte; Shelley L Deeks; Jianwei Zhou; Dennis K S Law; Saul Deng; Raymond S W Tsang
Journal:  J Med Microbiol       Date:  2012-10-04       Impact factor: 2.472

Review 9.  Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.

Authors:  Ouli Xie; Andrew J Pollard; Judith E Mueller; Gunnstein Norheim
Journal:  Vaccine       Date:  2013-04-24       Impact factor: 3.641

10.  Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003.

Authors:  Jianwei Zhou; Brigitte Lefebvre; Saul Deng; Rodica Gilca; Genevieve Deceuninck; Dennis K S Law; Philippe De Wals; Raymond S W Tsang
Journal:  J Clin Microbiol       Date:  2012-02-15       Impact factor: 5.948

View more
  3 in total

1.  Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of the current landscape of invasive meningococcal disease in children.

Authors:  Joan L Robinson; Sergio Fanella; Alison Lopez; Craig Frankel; Jane McDonald; Mohammad Alghounaim; Robert Slinger; Jennifer Bowes; Sarah Khan; Jeannette L Comeau; Kirk Leifso; John Gunawan; Michelle Barton
Journal:  Can Commun Dis Rep       Date:  2020-10-01

2.  Risk factors for carriage of meningococcus in third-level students in Ireland: an unsupervised machine learning approach.

Authors:  Richard J Drew; Desirée Bennett; Sinéad O'Donnell; Robert Mulhall; Robert Cunney
Journal:  Hum Vaccin Immunother       Date:  2021-06-24       Impact factor: 4.526

Review 3.  Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story.

Authors:  Philippe De Wals
Journal:  Can J Infect Dis Med Microbiol       Date:  2019-11-25       Impact factor: 2.471

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.